Processa PharmaceuticalsPCSA
13F holders, Q3 2024 (September 30)8holders −1
1new positions
2sold out
$1.37avg. 13F price*
At the end of Q3 2024, 8 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($33K), Geode Capital Management, LLC ($27K) and Tower Research Capital LLC (TRC) ($5K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C304
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $714 |
| Exits | 2 | $209 |
All 13F filers, Q2 2024 → Q3 2024: 3,621 shares bought and 104 shares sold, net +3,517 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Vanguard Group Inc. | 0.00% | No change | 24,433 | $33K |
| Geode Capital Management, LLC | 0.00% | Add +14.3% | 19,693 | $27K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +21.4% | 3,640 | $5K |
| UBS Group AG | 0.00% | New | 521 | $714 |
| Wells Fargo & Company | 0.00% | No change | 154 | $211 |
| Allworth Financial LP | 0.00% | No change | 85 | $117 |
| Bank of America Corp. | 0.00% | Add +14.3% | 24 | $33 |
| Macroview Investment Management LLC | 0.00% | No change | 1 | $2 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.